SCHOTT Pharma records good start into fiscal year and confirms full year outlook

“Following a very successful year 2024, we expected a softer start into 2025 and will now use our strong foundation to reach our full year targets. The additional capacities in glass syringes and sterile cartridges combined with secured contracts will drive the business performance in the second half of the year,“ said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.

Revenues remained stable; EBITDA in line with expectations

Revenues in Q1 2025 reached EUR 230m, reflecting a slight yoy decline of 1%. However, at constant currencies, revenues increased by 4%. Revenues were driven by a high demand for strong-margin high-value solutions (HVS), which contributed 55% of the total revenue share. This was mostly driven by a strong expansion of HVS in the Drug Containment Solutions (DCS) business.

SCHOTT Pharma’s EBITDA decreased to EUR 58m. As expected, the company experienced higher ramp-up costs compared to the prior year, a negative product mix impact, and saw FX-headwinds this fiscal year, while experiencing FX tailwinds last fiscal year. The resulting EBITDA margin amounted to 25.1%. At constant currencies, the EBITDA margin stood at 26.3%. The company is well on track to achieve the fiscal year guidance.

The DDS segment greatly benefitted from trends, such as GLP-1 and subcutaneous administration, which almost fully compensated the temporarily lower demand for some applications of polymer syringes. This resulted in largely stable revenues of EUR 101m in the first quarter and a reduced EBITDA of EUR 34m. In addition, the EBITDA included scale-up costs for capacity expansions in glass syringes and a negative product mix impact.

In the DCS segment, the good performance was primarily driven by a high demand for its HVS portfolio such as sterile cartridges and coated, ready-to-use vials, translating to strong revenues of EUR 129m in Q1 2025. On-going cost efficiency measures overcompensated ramp-up costs, and resulted in an increased EBITDA of EUR 28m and an improved margin.

Innovating along key pharma trends

Broadening its portfolio, SCHOTT Pharma recently launched its next-generation polymer syringe system SCHOTT TOPPAC® infuse, which is primarily used in hospital environments. The system addresses critical challenges, including high levels of medication waste, inefficient manual processes, and storage constraints. It also improves patient safety and sustainability across the entire value chain.

The expected stronger growth in DCS will be enabled by high-value solutions, such as coated specialty vials for ADCs and ready-to-use cartridges for GLP-1 drugs, and drugs administered subcutaneously.

Expansion projects proceeding according to schedule

To meet the increasing HVS demand in DCS, SCHOTT Pharma plans to further expand its manufacturing capacities for sterile cartridges.

Following the opening of the new production facility for prefillable glass syringes in Hungary in 2024, the company successfully completed audits from large key accounts and qualified products. Furthermore, SCHOTT Pharma expects commercial supply from its best-cost production site in Serbia to start by the end of the fiscal year 2025.

Outlook

SCHOTT Pharma confirms its fiscal year 2025 targets based on a stronger second half with higher revenues coming from additional production capacities in glass syringes and sterile cartridges to serve exciting contracts. Thus, the company projects strong revenue growth at constant currencies in the high single digits. SCHOTT Pharma forecasts an EBITDA margin approximately at the strong level of FY 2024 (26.9%) at constant currencies.

For additional news about SCHOTT Pharma please visit our media center.

Key Figures Q1 2025

(in EUR m)	Q1 24	Q1 25	△ yoy	Q1 25 (cc2)	△ yoy (cc2)
Revenues	232	230	-1%	242	+4%
DCS Revenues	129	129	0%	142	10%
DDS Revenues	103	101	-2%	100	-4%
HVS revenue share	53%	55%	+1pp
EBITDA	73	58	-20%	64	-13%
DCS EBITDA	27	28	5%	31	16%
DDS EBITDA	40	34	-14%	33	-16%
EBITDA margin (in %)	31.3%	25.1%	-6.1pp	26.3%	-5.0pp
DCS EBITDA margin	20.8%	21.9%	1.1pp	22.0%	1.1pp
DDS EBITDA margin	38.3%	33.7%	-4.6pp	33.4%	-4.8pp
EBIT	58	39	-32%
EBIT margin (in %)	25.0%	17.1%	-7.9pp
Earnings per share (in EUR)	0.29	0.19	-35%
Cash flow from operating activities	66	24	-42
Cash flow from investing activities	-29	-21	+8
Free cash flow	37	3	-34
Total clash CAPEX	-28	-21	+7

 

¹The fiscal year runs from October to September. Q1 2025 therefore relates to the period from October 2024 to December 2024.
²CC = at constant currencies

Webcast

Andreas Reisse (CEO) and Dr. Almuth Steinkühler (CFO) will speak at an analyst and investor conference call at 11:00 a.m. CET on 13 February 2025 to discuss the Q1 2025 results. The audio webcast can be followed via a conference call. The accompanying presentation can also be downloaded on the IR website: www.schott-pharma.com/investor-relations

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com